There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mesoblast (MESO) and Fate Therapeutics (FATE) with bullish sentiments.
Mesoblast (MESO)
In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on Mesoblast, with a price target of $18.00. The company’s shares closed last Friday at $7.21, close to its 52-week low of $6.67.
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 37.6% and a 45.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, SELLAS Life Sciences Group, and Lineage Cell Therapeutics.
Currently, the analyst consensus on Mesoblast is a Moderate Buy with an average price target of $17.00, implying a 135.8% upside from current levels. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
Fate Therapeutics (FATE)
Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Fate Therapeutics today and set a price target of $109.00. The company’s shares closed last Friday at $69.16.
According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 10.5% and a 34.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals.
Fate Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $112.29, which is a 67.0% upside from current levels. In a report issued on May 24, Jefferies also assigned a Buy rating to the stock with a $145.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
